NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO Announces Launch of First Generic Version of Pomalyst(r) (Pomalidomide) Capsules in the Australian Market09-11-2022
09-11-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 FY23 Financial Results Earnings Call on Friday 11th November 202203-11-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate01-11-2022
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Notice Of Board Meeting
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter and half year ended 30th September, 2022 and to consider 2nd interim dividend, if any, for the financial year 2022-23.31-10-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release21-10-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share Certificate14-10-2022
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended September 2022 (Revised)
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- CH VENKAT RAMESHDesignation :- Company Secretary and Compliance Officer12-10-2022
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- CH VENKAT RAMESHDesignation :- Company Secretary and Compliance Officer12-10-2022
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 202211-10-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches Chlorantraniliprole (CTPR) combination Agro Products in India04-10-2022